$UBX
Unity Biotechnology, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020035035 Filed on July 31, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.320M $4.910M $4.970M
YoY Change 27.16% 13.39% 29.43%
% of Gross Profit
Research & Development $16.12M $18.21M $18.47M
YoY Change -12.7% 11.51% 21.52%
% of Gross Profit
Depreciation & Amortization $910.0K $740.0K $640.0K
YoY Change 42.19% 23.33% 23.08%
% of Gross Profit
Operating Expenses $23.35M $23.09M $24.47M
YoY Change -4.58% 1.23% 17.66%
Operating Profit -$23.35M -$23.09M -$24.47M
YoY Change -4.58% 1.24% 17.66%
Interest Expense $0.00 $630.0K $900.0K
YoY Change -100.0% -41.12% 8.96%
% of Operating Profit
Other Income/Expense, Net $4.342M $4.440M -$103.0K
YoY Change -4315.53% -2566.67% 243.33%
Pretax Income -$18.67M -$18.03M -$23.67M
YoY Change -21.12% -17.75% 18.35%
Income Tax
% Of Pretax Income
Net Earnings -$18.67M -$18.03M -$23.67M
YoY Change -21.15% -17.75% 18.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.76 -$3.86 -$5.58
COMMON SHARES
Basic Shares Outstanding 45.94M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.5M $127.5M $128.0M
YoY Change -6.64% -25.48% -31.18%
Cash & Equivalents $39.59M $37.47M $23.11M
Short-Term Investments $79.90M $90.00M $104.9M
Other Short-Term Assets $4.000M $2.000M $2.800M
YoY Change 42.86% 11.11% 64.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $123.5M $129.5M $141.4M
YoY Change -12.68% -25.14% -24.62%
LONG-TERM ASSETS
Property, Plant & Equipment $39.10M $16.64M $5.658M
YoY Change 591.06% 166.69% -14.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $3.000M $4.000M
YoY Change -100.0% -66.94%
Other Assets $598.0K $627.0K $1.639M
YoY Change -63.51% -61.34% -25.5%
Total Long-Term Assets $41.20M $21.73M $12.78M
YoY Change 222.29% 158.43% -38.78%
TOTAL ASSETS
Total Short-Term Assets $123.5M $129.5M $141.4M
Total Long-Term Assets $41.20M $21.73M $12.78M
Total Assets $164.7M $151.2M $154.2M
YoY Change 6.8% -16.63% -26.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.952M $5.185M $5.381M
YoY Change -26.56% 6.97% 183.21%
Accrued Expenses $6.250M $4.995M $4.840M
YoY Change 29.13% 0.1% -0.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.67M $17.22M $15.23M
YoY Change 2.87% 3.82% 62.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.80M $13.30M $7.000K
YoY Change 525614.29% 29455.56% -91.46%
Total Long-Term Liabilities $36.80M $0.00 $7.000K
YoY Change 525614.29% -100.0% -91.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.67M $17.22M $15.23M
Total Long-Term Liabilities $36.80M $0.00 $7.000K
Total Liabilities $52.44M $30.51M $27.16M
YoY Change 93.07% 47.54% 102.88%
SHAREHOLDERS EQUITY
Retained Earnings -$292.2M -$245.5M -$205.7M
YoY Change 42.04% 50.33%
Common Stock $404.8M $366.7M $333.3M
YoY Change 21.46% 12.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.3M $120.7M $127.1M
YoY Change
Total Liabilities & Shareholders Equity $164.7M $151.2M $154.2M
YoY Change 6.8% -16.63% -26.04%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$18.67M -$18.03M -$23.67M
YoY Change -21.15% -17.75% 18.35%
Depreciation, Depletion And Amortization $910.0K $740.0K $640.0K
YoY Change 42.19% 23.33% 23.08%
Cash From Operating Activities -$19.29M -$15.69M -$19.30M
YoY Change -0.05% 22.58% 6.93%
INVESTING ACTIVITIES
Capital Expenditures $350.0K $610.0K $230.0K
YoY Change 52.17% 38.64% -46.51%
Acquisitions
YoY Change
Other Investing Activities $12.65M -$3.860M $7.510M
YoY Change 68.44% 614.81% -108.13%
Cash From Investing Activities $12.31M -$4.480M $7.280M
YoY Change 69.09% 352.53% -107.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.51M 20.87M 880.0K
YoY Change 2344.32% 6856.67% -98.93%
NET CHANGE
Cash From Operating Activities -19.29M -15.69M -19.30M
Cash From Investing Activities 12.31M -4.480M 7.280M
Cash From Financing Activities 21.51M 20.87M 880.0K
Net Change In Cash 14.53M 700.0K -11.14M
YoY Change -230.43% -105.19% -61.05%
FREE CASH FLOW
Cash From Operating Activities -$19.29M -$15.69M -$19.30M
Capital Expenditures $350.0K $610.0K $230.0K
Free Cash Flow -$19.64M -$16.30M -$19.53M
YoY Change 0.56% 23.11% 5.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5507000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1446000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
598000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17216000
ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
-213000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9447000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34973000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4079000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
385000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1999000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4001000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2019Q4 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
210000
CY2020Q2 us-gaap Liabilities
Liabilities
52439000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366695000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3025000
CY2019Q4 us-gaap Liabilities
Liabilities
30514000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
404754000
CY2020Q2 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
210000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
405000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
627000
CY2020Q2 us-gaap Assets
Assets
164698000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3952000
CY2019Q4 us-gaap Assets
Assets
151221000
CY2020Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3651000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5185000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6250000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5905000
CY2020Q2 ubx License Agreement Contingent Consideration Liability Current
LicenseAgreementContingentConsiderationLiabilityCurrent
1816000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4995000
CY2019Q4 ubx License Agreement Contingent Consideration Liability Current
LicenseAgreementContingentConsiderationLiabilityCurrent
1131000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15669000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M18D
CY2020Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
7768000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23349000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4342000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-103000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2933000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-139000
us-gaap Net Income Loss
NetIncomeLoss
-46705000
us-gaap Net Income Loss
NetIncomeLoss
-42440000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
208000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42232000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42442886
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42311040
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120707000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3225000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
283000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-28038000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
105329000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
355000
CY2020Q2 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
132000
CY2020Q2 ubx Repayment Of Promissory Note From Related Party From Purchase Of Common Stock
RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock
56000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18667000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
112259000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160693000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000
CY2019Q1 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
207000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1997000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2059000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
114000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18767000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6320000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4970000
us-gaap Operating Expenses
OperatingExpenses
50505000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18468000
CY2020Q2 ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
906000
CY2019Q2 ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
1032000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2159000
us-gaap Operating Expenses
OperatingExpenses
44207000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50505000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44207000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
867000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1906000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16123000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
24470000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24470000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
900000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23673000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
127050000
us-gaap Net Income Loss
NetIncomeLoss
-46705000
us-gaap Net Income Loss
NetIncomeLoss
-42440000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1814000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1280000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2271000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
965000
ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
470000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2002000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
766000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-29000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
17000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1262000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
391000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1446000
ubx Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
685000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
23349000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12273000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151221000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
418000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
232000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
90000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245455000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
112259000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120707000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164698000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51729511
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51729511
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47227065
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47227065
CY2020Q2 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
362000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36770000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
13298000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292160000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39897000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1031000
ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
279000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1163000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8610000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38919000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15949000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
377000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
437000
ubx Proceeds From Issuance Of Common Stock Under Equity Incentive Plans Net Of Repurchase
ProceedsFromIssuanceOfCommonStockUnderEquityIncentivePlansNetOfRepurchase
604000
ubx Proceeds From Issuance Of Common Stock Under Equity Incentive Plans Net Of Repurchase
ProceedsFromIssuanceOfCommonStockUnderEquityIncentivePlansNetOfRepurchase
794000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
56000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
38000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
36000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30501000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35388000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
340000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18667000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23673000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
142000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18808000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23579000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46563000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49659153
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48606768
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
249000
CY2020Q1 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
40000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
146603000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494000
CY2019Q2 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
218000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
94000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
54000
us-gaap Share Based Compensation
ShareBasedCompensation
7421000
us-gaap Share Based Compensation
ShareBasedCompensation
3941000
ubx Common Stock Issued To Third Party For License
CommonStockIssuedToThirdPartyForLicense
965000
ubx Non Cash Rent Expense
NonCashRentExpense
106000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2159000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
3060000
ubx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
685000
ubx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-213000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1050000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1005000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
50699000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
98480000
ubx Realized Gain On Sale Of Strategic Investments
RealizedGainOnSaleOfStrategicInvestments
799000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29494000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
385000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
405000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2119000
ubx Lessor Funded Lease Incentives Included In Tenant Improvement Receivable
LessorFundedLeaseIncentivesIncludedInTenantImprovementReceivable
10650000
ubx Issuance Of Shares In Settlement Of Share Based Liability
IssuanceOfSharesInSettlementOfShareBasedLiability
100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292200000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245500000
us-gaap Net Income Loss
NetIncomeLoss
-46700000
us-gaap Net Income Loss
NetIncomeLoss
-42400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39900000
CY2020Q2 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
111800000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41038000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability and stock-based compensation. Actual results could differ from such estimates or assumptions.</p>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39592000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37473000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38919000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments in marketable securities to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of June 30, 2020, the Company had no off-balance sheet concentrations of credit risk. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also exposed to market risk in its strategic investments. As of June 30, 2020, the Company held an investment in common stock which is publicly traded in Hong Kong.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020 the World Health Organization declared the global novel coronavirus (“COVID-19”) outbreak a pandemic. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and results of operations, including ongoing and planned clinical studies. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the COVID-19 pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s business, financial condition, results of operations and prospects may be adversely affected.  </p>
us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of June 30, 2020, the Company had no off-balance sheet concentrations of credit risk.
CY2020Q2 ubx Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
0
CY2020Q2 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49659153
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42442886
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
2200000
CY2020Q2 ubx Percentage Of Cumulative Probability Of Defined Milestones
PercentageOfCumulativeProbabilityOfDefinedMilestones
0.90
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
97224000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
234000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
97456000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
124368000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
124459000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
ubx Compound Library And Option Agreement Execution Month And Year
CompoundLibraryAndOptionAgreementExecutionMonthAndYear
2016-02
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1144000
us-gaap Operating Lease Cost
OperatingLeaseCost
2444000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
363000
us-gaap Variable Lease Cost
VariableLeaseCost
641000
ubx Impairment Of Operating Lease Right Of Use Asset
ImpairmentOfOperatingLeaseRightOfUseAsset
1157000
CY2020Q2 us-gaap Lease Cost
LeaseCost
1507000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
us-gaap Lease Cost
LeaseCost
4242000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
us-gaap Operating Lease Payments
OperatingLeasePayments
2557000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3241000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6653000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6283000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4810000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4964000
CY2020Q2 ubx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
27302000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
53253000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12171000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
41082000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4312000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36770000
ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
100000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48606768
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42311040
CY2019Q2 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000.0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18667000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6906898
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3272256
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.33
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
123191
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
587441
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.43
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9468522
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.11
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
200000
ubx Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward
13550
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3941000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4104000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1944000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7421000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23673000
us-gaap Net Income Loss
NetIncomeLoss
-46705000
us-gaap Net Income Loss
NetIncomeLoss
-42440000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10457637
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7581925

Files In Submission

Name View Source Status
0001564590-20-035035-index-headers.html Edgar Link pending
0001564590-20-035035-index.html Edgar Link pending
0001564590-20-035035.txt Edgar Link pending
0001564590-20-035035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gspdz1xnvl2w000001.jpg Edgar Link pending
gspdz1xnvl2w000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-10q_20200630.htm Edgar Link pending
ubx-10q_20200630_htm.xml Edgar Link completed
ubx-20200630.xsd Edgar Link pending
ubx-20200630_cal.xml Edgar Link unprocessable
ubx-20200630_def.xml Edgar Link unprocessable
ubx-20200630_lab.xml Edgar Link unprocessable
ubx-20200630_pre.xml Edgar Link unprocessable
ubx-ex11_94.htm Edgar Link pending
ubx-ex311_8.htm Edgar Link pending
ubx-ex312_6.htm Edgar Link pending
ubx-ex321_7.htm Edgar Link pending
ubx-ex51_162.htm Edgar Link pending